Comparison of alemtuzumab vs. antithymocyte globulin induction therapy in primary non-sensitized renal transplant patients treated with rapid steroid withdrawal

2015 ◽  
Vol 29 (7) ◽  
pp. 573-580 ◽  
Author(s):  
Harrison E. Saull ◽  
Cher Y. Enderby ◽  
Thomas A. Gonwa ◽  
Hani M. Wadei
Keyword(s):  
Renal Transplant ◽  
Induction Therapy ◽  
Antithymocyte Globulin ◽  
Steroid Withdrawal ◽  
Transplant Patients ◽  
Renal Transplant Patients

Administration of rabbit antithymocyte globulin (thymoglobulin) in ambulatory renal-transplant patients

2003 ◽  
Vol 75 (4) ◽  
pp. 488-489 ◽  
Author(s):  
Michael R. Marvin ◽  
Cathy Droogan ◽  
Deirdre Sawinski ◽  
David J. Cohen ◽  
Mark A. Hardy
Keyword(s):  
Renal Transplant ◽  
Antithymocyte Globulin ◽  
Transplant Patients ◽  
Rabbit Antithymocyte Globulin ◽  
Renal Transplant Patients

EXPERIENCE WITH TWO-DOSE DACLIZUMAB INDUCTION THERAPY IN PEDIATRIC RENAL TRANSPLANT PATIENTS

2010 ◽  
Vol 90 ◽  
pp. 1053
Author(s):  
S. Sevmis ◽  
A. Akdur ◽  
S. Aktas ◽  
E. Baskin ◽  
H. Karakayali ◽  
...  
Keyword(s):  
Renal Transplant ◽  
Induction Therapy ◽  
Transplant Patients ◽  
Pediatric Renal Transplant ◽  
Renal Transplant Patients

scholarly journals OUTCOME AFTER STEROID WITHDRAWAL IN ADULT RENAL TRANSPLANT PATIENTS RECEIVING TACROLIMUS-BASED IMMUNOSUPPRESSION.

2000 ◽  
Vol 69 (Supplement) ◽  
pp. S224
Author(s):  
Pradip K. Chakrabarti ◽  
Hsien Y. Wong ◽  
Atsushi Toyofuku ◽  
Velma P. Scantlebury ◽  
Mark L. Jordan ◽  
...  
Keyword(s):  
Renal Transplant ◽  
Steroid Withdrawal ◽  
Transplant Patients ◽  
Renal Transplant Patients

Effect of Interleukin-2 Receptor Antibody Induction Therapy on Survival in Renal Transplant Patients Receiving Tacrolimus

2020 ◽  
Vol 51 (5) ◽  
pp. 366-372
Author(s):  
Hatem Ali ◽  
Ajay Sharma ◽  
Ahmed Halawa
Keyword(s):  
Renal Transplant ◽  
Induction Therapy ◽  
Interleukin 2 ◽  
Receptor Blocker ◽  
Post Transplant ◽  
Transplant Patients ◽  
Induction Group ◽  
Significant Difference ◽  
Renal Transplant Patients ◽  
Standard Risk

Background: This study aims to assess outcomes of interleukin-2 (IL-2) receptor blocker induction therapy on allograft and patients’ outcomes in standard risk recipients in the tacrolimus era, analysing data form the British Renal Transplant Registry. Methods: The study population involved all standard-risk renal transplant patients from 2000 till 2015 who were registered in the UK transplant registry and followed up till May 2018. Standard risk transplants were defined as patients with <2DR mismatch, calculated reaction frequency <20%, live donors or donors after brain death and patients with no previous renal transplantation transplant. We used inverse probability weights to adjust different covariates between the groups. Cox regression analysis for adjusted data and treatment effects model were used to assess outcomes. Results: In all, 3,597 renal transplant patients were included in the study. Two groups were identified; induction group (n = 2,858) which included patients who received IL-2 receptor blocker induction therapy and the no-induction group (n = 739). There was no significant difference between both groups in terms of estimated glomerular filtration rate (eGFR) rate at 1-year post-transplant (correlation co-efficient = 1.224, 95% CI ranges from –0.347 to 2.796). Average eGFR was 59.922 mL/min/1.73 m2 in the induction group (SD 29.171) and 64.557 mL/min/1.73 m2 in the no-induction groups (SD 46.763). There was no significant difference between both groups regarding graft survival at 5 years post-transplant (hazard ratio [HR] 0.944, 95% CI ranges from 0.599 to 1.485, p = 0.804), patient survival at 5 years post-transplant (HR 0.809, 95% CI ranges from 0.477 to1.372, p = 0.433). Conclusion: In the standard risk renal transplant population, the IL2 receptor blocker induction regimen does not affect eGFR at 1 year or renal and graft outcomes at 5 years.

Sign in / Sign up

Export Citation Format

Share Document